← brief for 2026-09-20 · Slowing decline

Systematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathy

Paper No results yet Peer reviewed

Key takeaways

This review updates the treatment guidelines for membranous nephropathy, a kidney disease that causes protein in the urine. It compares different immune-suppressing drugs to help doctors choose the best option. The full details of the comparison are not in the short summary provided.

Who did this work

Reiji Takami (SHOWA Medical University Fujigaoka Hospital) · Hiroki Nishiwaki (SHOWA Medical University Fujigaoka Hospital) · Yasushi Tsujimoto (Okayama Psychiatric Medical Center) · Yuji Oe (Tohoku University) · Keisuke Onishi (Kagawa University) · Yuki Oba (Toranomon Hospital) · Shinnosuke Sugihara (Keio University) · Yoshitaka Miyaoka (Tokyo Medical University) · Mai Yoshida (Tohoku University) · Masahiko Yazawa (St. Marianna University School of Medicine) · Tadashi Sofue (Kagawa University) · Izaya Nakaya (Iwate Prefectural Central Hospital)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-19
https://doi.org/10.1007/s10157-026-02944-4